IDH2 and neoplasm: High prevalence of IDH mutations (Box 3) suggests their participation in the formation of a TME composition favorable for the outcome (172) and decreased leukocyte chemotaxis, leading to fewer tumor-associated immune cells and better treatment outcome (173).